Literature DB >> 21507078

Maximizing patient adherence for optimal outcomes in psoriasis.

A Bewley1, B Page.   

Abstract

Psoriasis is a chronic, disabling disease in which adherence to treatment is often poor. The aim of this article is to highlight the problem of adherence to long-term treatment in psoriasis and the factors that contribute to it, and to discuss how adherence, and thus outcomes, can be improved. This article is based on a presentation given by the authors at a satellite symposium held during the 19th Congress of the European Academy of Dermatology and Venereology, 6-10 October, 2010, in Gothenburg, Sweden. Adherence to topical medication is a major problem in psoriasis. Not only are prescriptions not being filled by patients (primary adherence) but topical medications are not being used as recommended (secondary adherence). The issue is complex due to the many factors which affect adherence, including efficacy, ease of use and convenience of application, and the healthcare professional-patient relationship. Due to the nature of the disease, patients suffer poor self-image and feel stigmatized, particularly when psoriasis is present on a visible part of the body. Consequently, the negative impact of psoriasis on patient quality of life underlies many adherence issues. It is therefore important for treatment to address the psychological aspects as well as the physical symptoms of psoriasis. Improvements in several areas of disease management may lead to benefits in medication adherence and hence clinical benefit. Prescribing therapy in line with patient preference for treatment vehicle and improving the healthcare professional-patient relationship may be key factors. Nurses have an important role in educating patients and delivering long-term care. This individualized, personal, approach may help improve treatment adherence, outcomes, and the quality of life for patients with psoriasis.
© 2011 The Authors. Journal of the European Academy of Dermatology and Venereology © 2011 European Academy of Dermatology and Venereology.

Entities:  

Mesh:

Year:  2011        PMID: 21507078     DOI: 10.1111/j.1468-3083.2011.04060.x

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   6.166


  35 in total

Review 1.  Early Recognition and Treatment Heralds Optimal Outcomes: the Benefits of Combined Rheumatology-Dermatology Clinics and Integrative Care of Psoriasis and Psoriatic Arthritis Patients.

Authors:  Teo Soleymani; Soumya M Reddy; Jeffrey M Cohen; Andrea L Neimann
Journal:  Curr Rheumatol Rep       Date:  2017-11-20       Impact factor: 4.592

2.  Treatment Satisfaction Among Patients with Moderate-to-severe Psoriasis.

Authors:  Tracey Finch; Tang Ngee Shim; Lesley Roberts; Oliver Johnson
Journal:  J Clin Aesthet Dermatol       Date:  2015-04

Review 3.  Enhancing Topical Pharmacotherapy for Acne and Rosacea: Vehicle Choices and Outcomes.

Authors:  Lawrence J Green; Edward Lain; Thomas Prunty; Robert Rhoades
Journal:  J Clin Aesthet Dermatol       Date:  2022-05

Review 4.  Using insights from behavioral economics and social psychology to help patients manage chronic diseases.

Authors:  Braden K Mogler; Suzanne B Shu; Craig R Fox; Noah J Goldstein; Ronald G Victor; José J Escarce; Martin F Shapiro
Journal:  J Gen Intern Med       Date:  2012-11-15       Impact factor: 5.128

Review 5.  Secukinumab: a review of the anti-IL-17A biologic for the treatment of psoriasis.

Authors:  Jillian Frieder; Dario Kivelevitch; Alan Menter
Journal:  Ther Adv Chronic Dis       Date:  2017-11-16       Impact factor: 5.091

6.  Fixed Combination Aerosol Foam Calcipotriene 0.005% (Cal) Plus Betamethasone Dipropionate 0.064% (BD) is More Efficacious than Cal or BD Aerosol Foam Alone for Psoriasis Vulgaris: A Randomized, Double-blind, Multicenter, Three-arm, Phase 2 Study.

Authors:  Mark Lebwohl; Stephen Tyring; Michael Bukhalo; Javier Alonso-Llamazares; Martin Olesen; David Lowson; Paul Yamauchi
Journal:  J Clin Aesthet Dermatol       Date:  2016-02-01

7.  Non-adherence to drug therapy and drug acquisition costs in a national population--a patient-based register study.

Authors:  Bo Hovstadius; Göran Petersson
Journal:  BMC Health Serv Res       Date:  2011-11-28       Impact factor: 2.655

8.  Efficacy of an innovative aerosol foam formulation of fixed combination calcipotriol plus betamethasone dipropionate in patients with psoriasis vulgaris.

Authors:  Catherine Queille-Roussel; Martin Olesen; John Villumsen; Jean-Philippe Lacour
Journal:  Clin Drug Investig       Date:  2015-04       Impact factor: 2.859

9.  Assessing adherence factors in patients under topical treatment: development of the Topical Therapy Adherence Questionnaire (TTAQ).

Authors:  Ina Zschocke; Ulrich Mrowietz; Annett Lotzin; Eleni Karakasili; Kristian Reich
Journal:  Arch Dermatol Res       Date:  2014-02-08       Impact factor: 3.017

10.  Calcipotriol/Betamethasone Dipropionate Aerosol Foam for Plaque Psoriasis: A Prospective, Observational, Non-Interventional, Single-Center Study of Patient Adherence and Satisfaction in Daily Use.

Authors:  Francisco José Navarro-Triviño; Mario Lozano-Lozano; Ricardo Ruiz-Villaverde
Journal:  Dermatol Pract Concept       Date:  2021-05-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.